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Cheshire, Warrington and Wiral (12,091mg) –18.2 fold difference. Imatinib, highest: 
East Anglia (370,461mg); lowest: Leicestershire and Lincolnshire (71,592mg) –5.2 
fold difference. Denosumab, highest: Cheshire, Warrington and Wiral (11,281DDD); 
lowest: Merseyside (0DDD). ConClusions: There are large variations in local pre-
scribing between different NICE-approved oncology drugs, which exceeds what 
might have been expected from variations in local demographics. The ongoing frag-
mentation of the NHS particularly with respect to specialised service provision will 
likely further exacerbate this geographical variability in coverage and potentially 
fuel a greater ‘postcode lottery.’
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CaNCer Drug FuNDiNg DeCisioNs iN the uK: iNNovatioN aND value iN 
the BiologiCs era
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objeCtives: To review evidence-based processes used in UK cancer fund-
ing decisions, using biologics in metastatic colorectal cancer (mCRC) as a case 
study. Methods: We conducted an analysis of the peer-reviewed literature report-
ing overall survival (OS) in mCRC in randomised clinical trials (RCTs) and in real 
world studies (RWSs). Additionally, we investigated the use of RCTs and RWSs in UK 
cancer drug funding decisions. Results: Recent RWSs report median OS levels in 
mCRC that are several months longer than those seen in pre-biologic RCTs (approxi-
mately 29.2 months in the post-biologic era versus 17.4 months pre-biologics, an 
incremental survival benefit of 11.8 months). The most recent data show real world 
median OS as long as 32 months. However, the scoring system for cancer funding 
decisions in the UK is currently predominantly focused on pre-launch RCT data, 
with no data drawn from RWSs referenced in National Institute for Health and Care 
Excellence (NICE) and Clinical Reference Group (CRG) evaluations. ConClusions: 
The current focus of the cancer funding scoring system on pre-launch RCTs may 
miss value gained from ‘innovation-in-use.’ Additionally, treatment holidays and 
sequencing steps could lead to further cost reductions that might increase value 
even without impact on OS. Therefore, NICE evaluations and the methodology for 
CRG scoring may undervalue the reality of real-world experience. The Cancer Drugs 
Fund (CDF) enables the UK National Health Service to realize the full scope of ben-
efits of innovative drugs, overcoming the deficiencies currently inherent in NICE and 
CRG processes. Therefore, considerations for delisting of drugs from the CDF should 
be made in the light of data from RWSs as well as pre-launch data.
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are treNDs iN sPeNDiNg oN oNCology treatmeNts sustaiNaBle?: 
aNalysis oF sales PatterNs iN major gloBal marKets
Manning R
Bates White Economic Consulting, Washington, DC, USA
objeCtives: Spending on oncology medications accounts for a growing share of 
total medical spending, raising questions about the financial sustainability of 
pricing regimes and continued progress against cancer. This research evaluates oncol-
ogy spending across product classes, shedding light on the impact of loss of exclu-
sivity (LOE) and new product entry in order to provide focus and an improved fact 
basis for discussions of financial sustainability in oncology treatment. Methods: 
Quarterly observations on national-level sales of oncology medication in each of the 
five largest European markets, the US and Japan are compiled from IMS Health data 
from 2001 to 2013. These data are evaluated by medication type (cytotoxics, hormonals 
and targeted therapies) and brand/generic/biologic status, to evaluate the impact of 
LOE and new product entry with an eye toward projecting future oncology spending. 
Spending levels on oncology products by therapy type, country and exclusivity status 
are juxtaposed with patterns of hyperlipidemia and anti-ulcer products to assess the 
differences in sales patterns as product classes mature and lose exclusivity. Results: 
Although there is considerable variation across countries, it is generally observed that 
small-molecule oncologic products experience a classic “patent cliff” around LOE. For 
example, total spending on cytotoxics (chemotherapy agents) in the US peaked in 
late 2011 and declined to 83% of peak levels by late 2013; generics comprised 12% of 
total spending in 2001, and 28% of total spending by late 2013. Targeted therapies, on 
the other hand, have experienced consistent sales growth, with much of that growth 
occurring for biologic therapies. ConClusions: Oncology spending in major global 
markets does not appear to be fundamentally unsustainable. Questions about future 
spending growth are appropriately focused on targeted therapies, particularly on 
biologic products, suggesting that the emergence of biosimilars will play a central 
role in shaping oncology spending in coming years.
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Breast CaNCer treatmeNts iN relatioN to overall sCores aND FiNal 
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objeCtives: To characterise UK Cancer Drug Fund (CDF) scoring of breast can-
cer drugs using the CDF prioritisation tool and to assess the final decisions made 
by the Chemotherapy Clinical Reference Group (CCRG) and the national CDF 
panel. Methods: The CDF decision summaries (available online at www.england.
nhs.uk/ourwork/pe/cdf/cdf-drug-sum) record the formal decisions of the CCRG in 
relation to drugs and drug indications that are reviewed for inclusion on the national 
CDF list. We reviewed the individual scoring for each treatment in the criteria using 
the CDF prioritisation tool. Assessed criteria included: magnitude of survival benefit 
(progression free survival and overall survival), quality of life, toxicity compared 
with existing therapies, degree of unmet clinical need, strength of evidence and 
total score. Results: Between April 2013 and May 2015, 15 decision summaries 
assessing 7 drugs for the treatment of breast cancer were reported by the CCRG. Of 
these summaries, 5 saw a positive overall decision and 10 were negative. The over-
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objeCtives: MCDA allows structured consideration of the many aspects of value 
appraisal in healthcare. This study explored the value of lenvatinib for RR-DTC using 
holistic MCDA (EVIDEM framework). Methods: The framework integrated 12 quan-
titative and 7 qualitative contextual criteria, each derived from fundamental ethical 
positions. By-criterion lenvatinib evidence matrices were designed for three countries 
(France, Italy, Spain) and two comparators (watch and wait, sorafenib) based on a 
systematic review and proprietary data. Value appraisal was performed by collecting 
weights (individual perspectives), scores (performance of lenvatinib) and qualitative 
inputs (impact of context) from three structured panel sessions designed to include 
patients, physicians, health economists and policy-decisionmakers, convened under 
the Chatham house rule. Value contributions (WeightsXScores) for each criterion and 
variability across individuals, countries and weighting methods were analyzed. Data 
on usefulness of the process were collected. Results: The greatest weights were 
given to criteria Comparative effectiveness together with Quality of evidence (Spain 
and Italy) or Disease severity (France). Across all countries and comparators, four cri-
teria contributed most to the value of lenvatinib (Comparative effectiveness [16-22%], 
Disease severity [16-22%], Unmet needs [14-21%], Quality of evidence [14-20%]), with 
contributions varying by comparator and country. Some negative contributions were 
observed for criteria Comparative safety (versus watch and wait) and Comparative 
economic consequences. The overall value of lenvatinib was positive across countries 
and comparators with variability across individuals, countries and weighting meth-
ods. Impacts of contextual criteria varied noticeably across countries, highlighting 
the importance of local consultation. Panelists reported the process contributed to 
their understanding of the intervention and its context and was helpful to express 
and share their perspectives and knowledge. ConClusions: Using MCDA-based 
holistic appraisal, the value of lenvatinib was assessed as consistently positive in the 
diverse treatment landscapes. The method provides a structured means to collect 
country-specific data and facilitates exchange across stakeholders.
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objeCtives: Cost-per-QALY (CPQ) threshold can be a useful tool for resource alloca-
tion decisions but also may constitute an obstacle in access to the most-innovative, 
often life-saving but also expensive medicines. Since cancer is a major challenge 
for all healthcare systems, we investigated the impact of CPQ policy on new cancer 
drug reimbursement in 6 Central and Eastern Europe (CEE) countries: Poland and 
Slovakia (CPQ-driven countries), Czech Republic and Hungary (CPQ-oriented coun-
tries), Croatia and Romania (non-CPQ countries). Methods: Basing on predefined 
criteria we selected 13 drug-indication pairs and considered their reimbursement 
status, time from registration to positive reimbursement decision and possible 
factors influencing reimbursement decision. Analyzes were performed for each 
selected country separately and in pairs grouped with regard to CPQ policy. The 
results were compared with indicators illustrating reimbursement systems, general 
cancer care and economics of participating countries. Results: Generally, in all 
participating countries, cancer drugs generating lower CPQ values were more likely 
to be reimbursed. Analysis based on multinomial model adjusting for factors that 
might impact reimbursement decision confirmed significant role of CPQ value of 
a drug and GDP per capita of a country. Medicines generating higher CPQ values or 
evaluated in countries with lower GDP per capita are less likely to obtain positive 
reimbursement decisions. ConClusions: CEE countries have a different approach 
to CpQ application in reimbursement decisions. Access to oncology treatment for 
patients in CEE seems to be affected and not necessary improved by CPQ imple-
mentation policy. Higher CPQ value results in more constrained access to cancer 
drugs and prolonged time to reimbursement decision. CPQ is not the only criterion 
in the reimbursement process and even when met does not inevitably transfer into 
positive reimbursement decision. It seems that currently factors related to economy 
of CEE countries may affect reimbursement by far more than strictly CPQ policy.
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are you at risK oF CaNCer? CoNsiDer Where you live iN eNglaND For 
aCCess to the most exPeNsive oNCology treatmeNts
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objeCtives: Access to drugs, particularly high cost oncology medicines, across 
England has frequently been accused to operate under a ‘postcode lottery’ where 
access varied depending on where you live. Since 2012, the National Institute of 
Health and Care Excellence (NICE) recommendations are mandated to be followed 
nationally within 90 days of issuing. Nevertheless, further regional/local restrictions 
upon usage are not uncommon that, along with the duration of NICE decision-
making and non-universal coverage of medicines by NICE, leads to variability in 
prescribing levels of high cost medicines. Furthermore, NHS commissioning of 
specialised services is moving towards increasing co-commissioning between the 
local Clinical Commissioning Group (CCG) teams and regional/local NHS England 
bodies (formally Area Teams), with diverse models of care and service specifica-
tions being set out as part of the NHS 5 Year Forward View. This research aims to 
evaluate the level of regional variation in NHS prescribing. Methods: All cancer 
drug prescribing data from the most recent NHS innovation scorecard heat map 
(July-September 2014) was extracted. Variations in prescribing across the 25 Area 
Teams per 100,000 population were identified. Results: Data for three oncology 
drugs was available: denosumab, imatinib and nilotinib; NICE has issued positive 
guidance for all of these. Stark variations in amount prescribed between differ-
ent area teams were apparent. Nilotinib, highest: Merseyside (220,385mg); lowest: 
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the 6 new oncology drugs reimbursed by AIFA in 2014 with average times from the 
national reimbursement decision to the regional one ranging from 3 months in 
Piemonte to 5 months in Emilia Romagna. The Lazio and Sardinia Regions have 
evaluated only 1 out of the 6 drugs with an access time of around 2.5 and 6 months, 
respectively. ConClusions: In Italy, the average times from the national reim-
bursement decisions to the regional evaluations aiming to the formulary inclusion 
vary widely between Regions.
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objeCtives: To undertake a pragmatic, comparative analysis of cancer care path-
ways to identify drivers of improving cancer survival across Europe, using colon 
cancer as a case study. Methods: We conducted a review of data from interna-
tional, European and UK cancer databases and registries, focusing on the identi-
fication of variations in overall and colon cancer care and survival. Additionally, 
we investigated variation in national access to, as well as utilisation and speed 
of adoption of, biologic cancer treatments, a recognised source of improving can-
cer outcomes worldwide. Results: Overall, outcomes for many tumour types 
continue to improve across Europe, including in regions with historically low 
survival such as Eastern Europe. Data on general cancer treatment reveal that 
the rate of innovative drug use in the UK has increased since 2009, just prior to 
the establishing of the Cancer Drugs Fund (CDF). Since the advent of the CDF, the 
UK has risen internationally from 11th place to 7th in terms of cancer survival 
rate; however, this improvement still leaves the UK as one of the lowest ranked 
European countries. Patients with colon cancer are ~20% less likely to receive 
biologics than those in other European countries; this may explain the results of 
other studies showing that survival rates in the UK continue to lag behind those 
in central Europe in the CDF/biologics era. ConClusions: Although survival rates 
continue to improve, there remain geographical disparities in some cancer types 
despite major advances in care pathways and treatment. The UK in particular 
continues to lag behind other countries. The CDF provides a vital service, giving 
patients access to innovative, life-extending treatments. The threat of losing this 
access route has serious implications for UK cancer treatment, which is already 
among the least successful in Europe.
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versus matCheD CaNCer-Free CoNtrols
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objeCtives: To provide an overview of drugs used by elderly in the year before 
colon cancer diagnosis and to compare this with a matched control group without 
cancer. Methods: Data were obtained from the population-based Netherlands 
Cancer Registry (NCR) and linked to the PHARMO Database Network, which 
includes complete longitudinal data obtained from out-patient pharmacies. All 
colon cancer patients aged ≥ 70 years diagnosed between 2000-2011 were included. 
Patients were matched 1:1 with controls on gender, year of birth and postal code. 
Differences in the proportion of users between cases and controls of each drug 
on WHO ATC-3 level were calculated using Chi2 tests. Drug use was defined in 
the year before colon cancer diagnosis or cohort entry date and during each quar-
ter of that year. Results: The study population consisted of 2,735 colon cancer 
patients and 2,735 matched cancer-free controls. 90% of cases and 69% of controls 
used ≥ 1 drug during the study period. The top 3 most frequently used drugs, 
based on the highest number of users among cases during the total year, were 
drugs for constipation (cases vs. controls 58% vs. 10%, p< 0.0001), antithrombotic 
agents (42% vs. 33%, p< 0.0001) and drugs for acid related disorders (35% vs. 22%, 
p< 0.0001). For all 3 drugs, the number of users in each quarter was higher among 
cases. Among cases, the number of users increased during the last quarter of 
the year for drugs for constipation (10% Q3 to 53% Q4) and drugs for acid related 
disorders (19% Q3 to 27% Q4). ConClusions: Our study demonstrates higher 
drug use among elderly colon cancer patients during the year before diagno-
sis as compared to a matched cancer-free control group, which increased even 
more during the last three months before colon cancer diagnosis. The effect of 
specific drugs on cancer treatment and outcome should be subject of further 
study.
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metastatiC Breast CaNCer (mBC) By liNe oF theraPy aND assoCiateD 
ChaNges over time
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objeCtives: Eribulin mesylate is a microtubule inhibitor FDA approved in 2010 
for patients with MBC after treatment with at least two prior chemotherapeutic 
regimens. This study utilized real-world claims data to evaluate the utilization of 
eribulin mesylate by line of therapy at two and five years post launch to deter-
mine the degree to which patterns of utilization by line of therapy and payer type 
change over time without an associated change in labeling. Methods: Using data 
from the Cardinal Health Specialty Solutions Revenue Cycle Management medical 
claims database, patients who received 2 or more eribulin administrations and 
completed therapy between May 2014 and April 2015 were included in the current 
analyses (n= 368). The distribution of this study group was compared to a similar 
patient population identified as having completed therapy between April 2011 and 
all scoring of drugs varied considerably, with scores ranging from 1 to 13 and with 
just under half of drugs (7/15) receiving a score of 1 or no score at all. In contrast, 
the quality of evidence provided by manufacturers varied to a much lesser extent, 
with the majority of drugs receiving a score of “B” which, according to the scor-
ing system, indicates one good-quality published Phase III randomised controlled 
trial. ConClusions: Understanding the way the UK CDF makes decisions on the 
provision of breast cancer treatments can help pharmaceutical companies prepare 
evidence in order to maximise market access. Identifying strengths and weaknesses 
in the scoring of previous submissions to the CDF can also optimise submissions to 
give patients with breast cancer the best chance of access to innovative medicines.
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siPuleuCel-t (ProveNge®): autoPsy oF aN iNNovative ChaNge oF 
ParaDigm iN CaNCer treatmeNt
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objeCtives: Approved by the Food and Drug Administration (FDA) in 2010, sipuleucel-
T was the first personalised “cancer vaccine” to treat prostate cancer in the meta-
static, non-symptomatic population of 30,000 men in the US. Sipuleucel-T is prepared 
individually for each patient and infused in three sessions over one-month. In 2015, 
sipuleucel-T’s owner, Dendreon, filed for bankruptcy. This search aimed to review how 
this innovative product failed to achieve commercial success. Methods: PubMed 
and internet search focused on pricing, reimbursement and market access. Results: 
Sipuleucel-T’s FDA approval was delayed by 3 years, reportedly because of the vac-
cine’s new mechanism of action. Sipuleucel-Twas cleared by the European Medicines 
Agency two years later, but other locations were not approached. It was priced at 
$93,000 for a course of treatment. The high price combined with the company’s late 
management of reimbursement of the vaccine by the US Centers for Medicare & 
Medicaid Services (CMS) resulted in another year of delay in accessing the market. In 
spite of positive recommendation by the National Comprehensive Cancer Network, 
sipuleucel-T’s complex administration, high price and uncertainty about the reim-
bursement status deterred doctors from the product. Further, the vaccine’s supply was 
limited during the first year of launch, due to small manufacturing capacity. Two oral 
metastatic prostate cancer drugs with similar survival benefit reached the US market 
one and two years after sipuleucel-T. Even though Dendreon’s market capitalization 
topped $7.5 billion following FDA’s approval sipuleucel-T, this value degraded gradu-
ally until the firm’s bankruptcy five years later. ConClusions: The bankruptcy of 
Dendreon was largely due to the delay in reaching FDA approval and CMS coverage 
and the high cost that had to be incurred by providers up-front. Licensing sipuleucel-
T to a Pharma company more experienced in the market access pathway may have 
saved the company and the product.
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objeCtives: Access for oncology drugs can be severely constrained under obligate 
cost-utility HTA bodies, such as the SMC, NICE, pCODR and PBAC. Indeed the rejection 
rate for NICE oncology single technology appraisals is over three-times that of non-
oncology ones (40% vs. 13%). In April 2014, the SMC announced it would adopt a more 
flexible approach in its review of end-of-life and orphan therapies. Going forwards, 
if the initial SMC advice is not to recommend, a Patient and Clinician Engagement 
Group (PACE) meeting can be convened. This meeting aims to capture the benefits 
of the medicine outside of the considerations of the conventional process and was 
anticipated to constitute a “major factor” in the SMC decision. This research aims to 
evaluate what effect PACE groups have had on SMC appraisal outcomes. Methods: 
All SMC approvals from April 2014 were identified and the recommendation, indica-
tion and whether a PACE meeting was convened was extracted. Results: 87 SMC 
appraisals were identified, 46 were recommended, 26 were approved with restrictions 
and 15 were not recommended. 25 appraisals were for oncology drugs, 28% of which 
(7/25) were rejected compared to 13% (8/62) of non-oncologics. PACE meetings were 
convened in 20 appraisals 11 of which were recommended, 4 restricted and 5 rejected. 
19/20 were for oncology drugs, representing 76% (19/25) of all oncology apprais-
als. ConClusions: This new SMC PACE process is being well utilized, particularly 
in the appraisals of oncologics, and has resulted in many appraisals that would have 
been rejected being recommended instead. This has produced more timely market 
access for patients, without the need for multiple rounds of resubmissions, as was 
often the case pre-PACE. Nevertheless, rejection rates of oncology drugs still remain 
substantially higher than for non-oncology drugs.
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Four regioNs
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objeCtives: In Italy, federalism in health system leads to an increasingly frag-
mented and geographically differentiated Health, often even within the same region 
and also leads to a long and complex process for drugs market access and to get 
the access of patients. We conducted a survey in four regions in order to assess the 
inclusion of new cancer drugs within the regional formularies evaluating the time 
to access. Methods: Once a drug is reimbursed by the national assessment body 
(AIFA), a further step consists in obtaining the authorization for reimbursement 
by the regional health systems (RHS), many of which have their own formulary 
of reimbursed pharmaceutical drugs. Currently, 16 Italian regions have adopted 
a regional formulary. The selected Regions for this analysis are Emilia Romagna, 
Piemonte, Lazio and Sardegna. We considered six new oncology drugs reimbursed 
by AIFA in 2014, excluding three oncology drugs that bypass the regional evaluation 
process since they respond to the requirement of therapeutic innovation. Results: 
Nowadays, only the Regions of Piemonte and Emilia Romagna have evaluated all 
